Dataset from Phase 2/3, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study To Evaluate the Efficacy and Safety of Certolizumab Pegol in Japanese Subjects With Moderate to Severe Chronic Psoriasis
收藏NIAID Data Ecosystem2026-05-10 收录
下载链接：
https://doi.org/10.25934/PR00007867
下载链接
链接失效反馈官方服务：
资源简介：
The purpose of this study is to demonstrate the efficacy and safety of Certolizumab Pegol
(CZP) in the treatment of moderate to severe chronic plaque Psoriasis (PSO) in Japanese
subjects.
创建时间：
2026-03-13
